Background
KRAS G12D is the most common KRAS variant in pancreatic cancer but has historically been undruggable. Setidegrasib (ASP3082) is a first-in-class targeted protein degrader designed to eliminate KRAS G12D protein rather than merely inhibit it.
Results
In this first-in-human phase 1 study, among 21 patients with metastatic PDAC receiving the 600 mg dose, 24% achieved an objective response.
In NSCLC (n=45), the objective response rate was 36% with a median PFS of 8.3 months.